Clinical Study

British Journal of Cancer (2008) 98, 542–546. doi:10.1038/sj.bjc.6604188 www.bjcancer.com
Published online 22 January 2008

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group

J G Kim1, S K Sohn1, Y S Chae1, H S Song2, K-Y Kwon2, Y R Do2, M K Kim3, K H Lee3, M S Hyun3, H M Ryoo4, S H Bae4, K U Park5, W S Lee6, J H Baek7, H Y Chung8 and W Yu8

  1. 1Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea
  2. 2Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
  3. 3Department of Oncology/Hematology, Yeungnam University Hospital, Daegu, Korea
  4. 4Department of Oncology/Hematology, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea
  5. 5Department of Oncology/Hematology, Dongguk University Medical Center, Dongguk University College of Medicine, Gyeongju, Korea
  6. 6Department of Oncology/Hematology, Daegu Fatima Hospital, Daegu, Korea
  7. 7Department of Oncology/Hematology, Ulsan University Hospital, Ulsan, Korea
  8. 8Department of General Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea

Correspondence: Dr HS Song, Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, 194 Dongsan-dong, Jung-ku, Daegu 700-712, Korea. E-mail: shs7436@dsmc.or.kr

Received 7 August 2007; Revised 4 December 2007; Accepted 12 December 2007; Published online 22 January 2008.

Top

Abstract

The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous docetaxel 65 mg m-2 plus oxaliplatin 120 mg m-2 on day 1 based on a 3-week cycle. Forty-two patients were enrolled in the current study, among whom 39 were assessable for efficacy and all assessable for toxicity. One complete response and 18 partial responses were confirmed, giving an overall response rate of 45.2% (95% confidence interval (CI); 31.7–59.7%). At a median follow-up of 7.7 months, the median time to progression and median overall survival was 5.7 (95% CI; 4.3–7.2) months and 9.9 (95% CI; 7.8–12.0) months, respectively. Grade 3/4 neutropenia occurred in 11 patients (26.1%) and febrile neutropenia was observed in four patients (9.5%). The common non-haematologic toxicity was fatigue (grade 1/2, 61.9%) and nausea (grade 1/2, 47.7%). The combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.

Keywords:

docetaxel, oxaliplatin, chemotherapy, gastric cancer